Found 8 matching trials
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma PHASE1 This research study is studying a combination of targeted therapies as a po...
Show More Location
Dana Farber Cancer Institute
Learn More & Join Trial
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases PHASE1 This study will evaluate the safety and efficacy of MCS110 in patients with...
Show More Location
NV Cancer Institute
Learn More & Join Trial
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer PHASE2 \<Background\>
1. Current status of treatment options in advanced gastric ...
Show More Location
Seoul National University Hospital
Learn More & Join Trial
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies PHASE1 The purpose of this study of MCS110 with PDR001 was to characterize the saf...
Show More Location
Dana Farber Cancer Center
Learn More & Join Trial
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). PHASE1 This is a Phase Ib, open label, dose escalation study of spartalizumab + LA...
Show More Location
Columbia University Medical Center- New York Presbyterian Columbia
Learn More & Join Trial
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer PHASE1 In patients with locally advanced hormone receptor positive (HR+)/HER2- bre...
Show More Location
Multiple Locations
Learn More & Join Trial
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) PHASE2 To determine whether MCS110 antibody therapy improves the efficacy of carbo...
Show More Location
Highlands Oncology Group
Learn More & Join Trial
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) PHASE2 This study, designed as a proof of concept study of MCS110 in pigmented vil...
Show More Location
Novartis Investigative Site
Learn More & Join Trial